Measurement of HO2 and other trace gases in the stratosphere using a high resolution far-infrared spectrometer

This report covers the time period 1 January 1994 to 31 December 1994. During this reporting period we had our fourth Upper Atmosphere Research Satellite (UARS) correlative balloon flight; the data from this flight have been reduced and submitted to the UARS CDHF. We have spent most of the past year analyzing data from this and past flights. For example, using data from our September 1989 balloon flight we have demonstrated for the first time ever that the rates of production and loss of ozone are in balance in the upper stratosphere. As part of this analysis, we have completed the most detailed study to date of radical partitioning throughout the stratosphere. We have also produced the first measurement of HBr and HOBr mixing ratio profiles over a full diurnal cycle

Measurement of HO2 and other trace gases in the stratosphere using a high resolution far-infrared spectrometer

This report covers the time period 1 Jul. to 31 Dec. 1993. There were no balloon or airplane flights during this reporting period, instead we concentrated on analyzing our existing data. This was facilitated by a recently completed program of enhancements made in our data reduction software. We are using our data sets to examine the changes in stratospheric chemistry over a variety of time scales. Ongoing projects include investigating the diurnal variation of OH, HO2, and H2O2 and exploring their relationships with other simultaneously measured species; measuring long term trends in HF and HCl; and looking for changes caused by the June 1991 Pinatubo eruption. We are also continuing to analyze the large set of data collected during the AASE 2

Comparisons of clinical outcomes between newly diagnosed early- and late-onset T2DM: a real-world study from the Shanghai Hospital Link Database

Objective: The aim of this study was to compare the differences in incident population, comorbidities, and glucose-lowering drug prescriptions between newly diagnosed patients with early-onset type 2 diabetes mellitus (T2DM) and those with late-onset T2DM to provide real-world evidence for clinical practice. Methods: This study was based on the Shanghai Hospital Link Database (SHLD). Anonymized electronic medical record (EHR) data from 2013 to 2021 were included in this study. Newly diagnosed patients with T2DM were defined as those without related diagnostic records or glucose-lowering medicine prescriptions in the past 3 years. Early-onset T2DM was defined as patients who were aged 18–40 years old at the first visit for T2DM to represent those who were born after the 1980s. And late-onset T2DM was defined as those aged 65–80 years old to represent those who were born in a relatively undeveloped period. Descriptive statistical analyses were performed to describe their incidence number, glucose-lowering drug prescriptions, and comorbidities at the first visit to the hospital between two T2DM groups. Results: There were a total of 35,457 newly diagnosed patients with early-onset T2DM and 149,108 newly diagnosed patients with late-onset T2DM included in this study. Patients with late-onset T2DM constituted the majority and their number increased by 2.5% on average by years, while the number of patients with early-onset T2DM remained stable each year. Compared with late-onset T2DM patients, more early-onset T2DM patients had dyslipidemia at the first visit to hospitals (9.5% vs 7.7%, P < 0.01) despite their significant age differences. Patients with early-onset T2DM were more likely to use metformin (74.8% vs 46.5, P < 0.01), dipeptidyl peptidase-4 inhibitors (DDP-4i) (16.7% vs 11.2%, P < 0.01), thiazolidinediones (TZD) (14.9% vs 8.4%, P < 0.01), sodium glucose cotransporter 2 inhibitors (SGLT2-i) (0.8% vs 0.3%, P < 0.01), and glucagon-like peptide 1 receptor agonists (GLP-1 RA) (3.7% vs 0.5%, P < 0.01) at their first visit to the hospital. Conclusions: Different characteristics were observed between patients with early-onset T2DM and those with late-onset T2DM. Compared with patients with late-onset T2DM, those with early-onset T2DM were more prone to dyslipidemia and had novel organ-protective drugs prescribed